Qelbree vs. Strattera: How do they compare?
Overview
In this article, we'll review Qelbree and Strattera and the differences that might matter to you when deciding on an ADHD treatment.
Attention deficit hyperactivity disorder (ADHD) is a common condition marked by ongoing issues related to attention, hyperactivity, and impulsiveness that can interfere with learning, development and daily functioning. It can occur in school aged children and adolescents and often persists into adulthood. In the U.S., about 9.4% of children and 1% to 5% of adults are estimated to have ADHD.
Table 1: Selective Norepinephrine Reuptake Inhibitors (Nonstimulants for ADHD)
Product Availability | Duration / Dose frequency | Cost Comparison |
Qelbree (viloxazine ER) | Given once per day. Lasts throughout the day. May take 2 to 6 weeks for full effect. Can be swallowed whole or sprinkled onto one teaspoonful of applesauce or pudding and swallowed immediately without chewing. Do not chew or crush the capsules. May take with or without food. | |
Strattera (atomoxetine) | At least 10 to 12 hours duration; up to 24 hours. May take 1 to 4 weeks for full effect. Can give once per day OR dose may be divided and given in the morning and late afternoon / early evening. Do not chew, crush, or open the capsules. Tell your doctor if you or your child cannot swallow Strattera whole because a different medicine may need to be prescribed. Don't touch a broken or open Strattera capsule. Wash your hands and any surfaces that may have touched an open capsule. May take with or without food. | |
How do side effects compare between Qelbree and Strattera?
Both Qelbree and Strattera have Boxed Warnings (FDA’s most prominent warning) for an increased risk of suicidal thoughts and actions in children and adolescents with ADHD, especially within the first few months of treatment or when the dose is changed.
There is a very important drug interaction with both of these medicines. You should NOT use either of these medicines if you are taking or have taken within the past 14 days an antidepressant medicine called a monoamine oxidase inhibitor (MAOI). The combination can lead to a variety of serious side effects, including dangerously high blood pressure and even death. If you are not sure if you take an MAOI, ask your pharmacist. MAOIs are not prescribed very often today.
If you or your child have high blood pressure, a heart rate disorder or other heart problems, be sure to tell your doctor before you are treated with either of these medicines.
Let your doctor know if you have a history of bipolar disorder, depression, mania or hypomania before you start treatment with Qelbree or Strattera. In people with untreated bipolar disorder, use of these medicines can lead to mania (an extreme increase in activity, talking, lack of sleep and risk for dangerous behaviors).
Both drugs can also cause drowsiness or fatigue and these are common side effects. Do not drive or operate heavy machinery until you know how the medicine will affect you.
Do not use Strattera if you:
Do not use Qelbree if you:
Warnings and Side Effects
Qelbree warnings include: Suicidal thoughts and behaviors, increases in blood pressure and heart rate, worsening of mania or hypomania (a type of mental health disorder), somnolence and fatigue (drowsiness, tiredness). Patients should be monitored for changes in weight.
In studies, most patients continued Qelbree treatment. About 3% of patients stopped treatment due to a side effect, with somnolence (drowsiness) being the main reason patients stopped therapy.
In clinical trials for Qelbree, the most common side effects included:
Strattera
Strattera warnings include: suicidal thoughts and behaviors, severe liver injury, serious cardiovascular events (sudden death, stroke and heart attack), increase in blood pressure and heart rate, allergic reactions, changes in urination, priapism. May cause or worsen aggressive, hostile behavior or certain mental health disorders like mania, bipolar disorder or psychosis. Children should be monitored for changes in weight / height.
Avoid touching a broken or open Strattera capsule. Wash your hands and any surfaces that may have touched an open capsule. If any of the powder gets in your eyes or your child’s eyes, rinse them with water right away and call your doctor.
Serious side effects include: serious allergic reactions (call your doctor if you have trouble breathing, see swelling or hives, or experience other allergic reactions), slowing of growth (height and weight) in children, problems passing urine including, trouble starting or keeping a urine stream, cannot fully empty the bladder.
Priapism (erections that won’t go away) have occurred rarely during treatment with Strattera. If you have an erection lasting longer than 4 hours, seek medical help / call 911 right away.
In studies, 3% of patients stopped Strattera treatment due to side effects. The top reasons treatment was stopped was due to irritability or somnolence (drowsiness) in children and insomnia, nausea, and chest pain in adults.
In clinical trials for Strattera, common side effects include:
This is not a complete list of possible warnings or side effects. Call your doctor for medical advice about side effects.
Which is more effective, Qelbree or Strattera?
Head-to-head, randomized, controlled studies comparing Qelbree with Strattera are not available, so it is not possible to say which one is more effective. They both have been shown to be effective options for treating ADHD in studies when compared to a placebo (a pill with no active ingredient).
Initially, stimulants like Adderall or Ritalin are considered more effective for treating ADHD symptoms than Qelbree or Strattera. Stimulants are typically used as a first-line treatment when possible; however, effectiveness can vary among individuals. Some individuals may have better results with the nonstimulants or tolerate them better.
In Phase 3, placebo controlled clinical studies, both Qelbree and Strattera have been shown to be effective in the treatment of ADHD in adults and children 6 years of age and older. Selection of one product over the other may depend upon your preference or that of your healthcare provider, considering side effects, dosage and cost.
However, nonstimulants like Qelbree or Strattera may be preferred agents for treatment of ADHD in patients who have or live in households where substance abuse is a concern. They may also be preferred for children with tics, Tourettes or who have had previous severe side effects with stimulants.
Other nonstimulant medications for ADHD include the alpha2-agonists clonidine extended-release (Kapvay and generics) and guanfacine extended-release (Intuniv and generics), but they are also less effective than stimulants for first-line treatment.
Can I get addicted to Qelbree or Strattera?
These medicine have not been reported to be habit-forming or cause withdrawal symptoms or dependence.
Qelbree or Strattera are not controlled substances. They are nonstimulant medications and are alternatives to immediate-release stimulant medications (for example, Ritalin or Adderall) for people with substance abuse concerns or that cannot tolerate stimulant side effects.
How do drug interactions compare between these agents?
Both Qelbree and Strattera have the potential for significant drug interactions because they affect cytochrome (CYP) P450 enzymes in the liver that may change blood levels of drugs in your body. This could lead to an increased risk of side effects. In some cases, your doctor may need to adjust your doses of medications or select an alternative treatment.
Be sure your doctor or pharmacist screens for drug interactions with any medicines you take, including prescription, over-the-counter, vitamins, and herbal or other dietary supplements. Do not start or stop any new medicine during treatment without first talking to your healthcare provider. Your doctor can decide if it is safe for you to combine medicines.
DO NOT USE Qelbree or Strattera with monoamine oxidase inhibitors (MAOIs), or within 2 weeks after stopping MAOIs. Combined use may lead to side effects that could be deadly.
Qelbree
Qelbree (viloxazine) is a strong CYP1A2 inhibitor. You should not use this medicine with certain other medicines that are CYP1A2 substrates, because blood levels of those medicines may increase and cause side effects. Tell your doctor if you or your child take: MAOIs, alosetron, duloxetine, ramelteon, tasimelteon, tizanidine or theophylline.
Qelbree is also a weak inhibitor of CYP2D6 and CYP3A4 and may lead to increases in blood levels of drugs that depend upon these enzymes for breakdown and excretion in the body. Your doctor or pharmacist can screen for these possible drug interactions. Your doctor can monitor you for side effects or adjust doses if needed.
Strattera
Tell your doctor if you are or child take any antidepressants, asthma medication, blood pressure medicine, or cold or allergy medicine that contains a decongestant (such as pseudoephedrine or phenylephrine). or blood pressure.
Dose adjustments may be needed if Strattera (atomoxetine) is used with potent CYP2D6 inhibitors or if used in patients known to be CYP2D6 poor metabolizers.
Use of Strattera with CYP2D6 inhibitors (for example: paroxetine, fluoxetine, and quinidine) may significantly increase atomoxetine blood levels in some patients (extensive metabolizers). Increased Strattera blood levels can occur, and may lead to side effects such as dizziness, dry mouth, loss of appetite, sleep disturbances, and heart palpitations.
Bottom Line
This is not all the information you need to know about Qelbree (viloxazine) or Strattera (atomoxetine) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.
Related medical questions
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions